THE USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF EBOLA VIRUS DISEASE

Abstract

Some drugs candidates for treatment of Ebola virus disease (EVD), have been studied, monoclonal antibody (mAb) cocktails have shown great potential as EVD therapeutics. The advantages of mAb therapy include low toxicity, high specificity and versatility, with the range of biological effects being dependent upon the Fc region. Functions of mAbs include pathogen opsonisation, complement activation, antibody-dependent cell cytotoxicity and virus neutralization characteristics. The most known mAb cocktail, used as therapeutic, is ZMapр, manufactured by Leaf Biopharmaceutical from 2004. The elaborated mAb cocktails, structures and properties s of mAbs, the protective characteristics of mAbs and development of new pan-ebolavirus mAbs are reviewed in this article.

Keywords

• review
• ebola virus
• hemorrhagic fever
• drugs
• current
• monoclonal antibodies
• nonhuman primates